STOCK TITAN

[8-K] Veritex Holdings, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Omeros Corporation (OMER) filed a Form 4 disclosing that non-employee director Dr. Leroy E. Hood received an annual stock-option grant for 15,000 shares on 27 Jun 2025. The option carries a $3.20 exercise price, a 10-year term expiring 27 Jun 2035, and will vest in full the day before the 2026 annual shareholder meeting provided he remains a director. No open-market purchases or sales of common stock were reported, and Table I shows no change in non-derivative share ownership. The filing reflects routine director compensation and represents a negligible portion of Omeros’ total shares outstanding, implying minimal immediate dilution or market impact.

Omeros Corporation (OMER) ha presentato un Modulo 4 comunicando che il direttore non dipendente Dr. Leroy E. Hood ha ricevuto un assegnazione annuale di opzioni su azioni per 15.000 titoli il 27 giugno 2025. L'opzione ha un prezzo di esercizio di 3,20 $, una durata di 10 anni con scadenza il 27 giugno 2035, e maturerà completamente il giorno prima dell'assemblea annuale degli azionisti del 2026, a condizione che rimanga direttore. Non sono stati segnalati acquisti o vendite sul mercato aperto di azioni ordinarie e la Tabella I non mostra variazioni nella proprietà di azioni non derivate. La comunicazione riflette la remunerazione ordinaria dei direttori e rappresenta una quota trascurabile del totale delle azioni in circolazione di Omeros, implicando un impatto minimo immediato in termini di diluizione o sul mercato.

Omeros Corporation (OMER) presentó un Formulario 4 revelando que el director externo Dr. Leroy E. Hood recibió una concesión anual de opciones sobre acciones por 15,000 títulos el 27 de junio de 2025. La opción tiene un precio de ejercicio de 3,20 $, un plazo de 10 años que vence el 27 de junio de 2035, y se consolidará en su totalidad el día antes de la junta anual de accionistas de 2026, siempre que siga siendo director. No se reportaron compras o ventas en el mercado abierto de acciones ordinarias y la Tabla I no muestra cambios en la propiedad de acciones no derivadas. La presentación refleja la compensación habitual de los directores y representa una porción insignificante del total de acciones en circulación de Omeros, lo que implica un impacto mínimo inmediato en dilución o en el mercado.

Omeros Corporation (OMER)는 Form 4를 제출하여 비임원 이사인 Dr. Leroy E. Hood가 2025년 6월 27일에 연간 주식매수선택권 15,000주를 부여받았음을 공개했습니다. 이 옵션은 행사가격이 3.20달러이며, 10년 만기로 2035년 6월 27일에 만료되고, 2026년 연례 주주총회 전날에 전액 취득 조건이며, 그가 이사로 남아 있는 경우에 한합니다. 보통주에 대한 공개 시장에서의 매매는 보고되지 않았으며, 표 I에서는 비파생 주식 소유에 변화가 없습니다. 이 제출은 정기적인 이사 보상을 반영하며 Omeros의 총 발행 주식 중 극히 일부에 해당하여 즉각적인 희석이나 시장 영향이 거의 없음을 의미합니다.

Omeros Corporation (OMER) a déposé un formulaire 4 indiquant que le directeur non salarié Dr Leroy E. Hood a reçu une attribution annuelle d’options sur actions pour 15 000 actions le 27 juin 2025. L’option comporte un prix d’exercice de 3,20 $, une durée de 10 ans expirant le 27 juin 2035, et sera entièrement acquise la veille de l’assemblée annuelle des actionnaires de 2026, à condition qu’il reste directeur. Aucun achat ou vente d’actions ordinaires sur le marché ouvert n’a été signalé, et le tableau I ne montre aucun changement dans la détention d’actions non dérivées. Le dépôt reflète la rémunération habituelle des administrateurs et représente une part négligeable du total des actions en circulation d’Omeros, impliquant un impact immédiat minimal en termes de dilution ou sur le marché.

Omeros Corporation (OMER) hat ein Formular 4 eingereicht, in dem offengelegt wird, dass der nicht-geschäftsführende Direktor Dr. Leroy E. Hood am 27. Juni 2025 eine jährliche Aktienoptionszuteilung für 15.000 Aktien erhalten hat. Die Option hat einen Ausübungspreis von 3,20 $, eine Laufzeit von 10 Jahren bis zum 27. Juni 2035 und wird am Tag vor der jährlichen Hauptversammlung 2026 vollständig unverfallbar, vorausgesetzt, er bleibt Direktor. Es wurden keine Käufe oder Verkäufe von Stammaktien am offenen Markt gemeldet, und Tabelle I zeigt keine Änderung im Besitz nicht-derivativer Aktien. Die Meldung spiegelt die routinemäßige Vergütung von Direktoren wider und stellt einen vernachlässigbaren Anteil der insgesamt ausstehenden Aktien von Omeros dar, was auf eine minimale unmittelbare Verwässerung oder Marktwirkung hindeutet.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine annual option grant; neutral impact on valuation or sentiment.

This Form 4 records the standard 15 k option award for non-employee directors under Omeros’ compensation policy. The $3.20 strike aligns with prevailing market levels, so the grant is neither a bargain purchase nor a bullish signal. With tens of millions of shares outstanding, 15 k options are immaterial for dilution and unlikely to influence trading dynamics. Because no open-market transactions occurred, the filing offers limited insight into insider conviction. I view the disclosure as administrative and not materially impactful for investors.

Omeros Corporation (OMER) ha presentato un Modulo 4 comunicando che il direttore non dipendente Dr. Leroy E. Hood ha ricevuto un assegnazione annuale di opzioni su azioni per 15.000 titoli il 27 giugno 2025. L'opzione ha un prezzo di esercizio di 3,20 $, una durata di 10 anni con scadenza il 27 giugno 2035, e maturerà completamente il giorno prima dell'assemblea annuale degli azionisti del 2026, a condizione che rimanga direttore. Non sono stati segnalati acquisti o vendite sul mercato aperto di azioni ordinarie e la Tabella I non mostra variazioni nella proprietà di azioni non derivate. La comunicazione riflette la remunerazione ordinaria dei direttori e rappresenta una quota trascurabile del totale delle azioni in circolazione di Omeros, implicando un impatto minimo immediato in termini di diluizione o sul mercato.

Omeros Corporation (OMER) presentó un Formulario 4 revelando que el director externo Dr. Leroy E. Hood recibió una concesión anual de opciones sobre acciones por 15,000 títulos el 27 de junio de 2025. La opción tiene un precio de ejercicio de 3,20 $, un plazo de 10 años que vence el 27 de junio de 2035, y se consolidará en su totalidad el día antes de la junta anual de accionistas de 2026, siempre que siga siendo director. No se reportaron compras o ventas en el mercado abierto de acciones ordinarias y la Tabla I no muestra cambios en la propiedad de acciones no derivadas. La presentación refleja la compensación habitual de los directores y representa una porción insignificante del total de acciones en circulación de Omeros, lo que implica un impacto mínimo inmediato en dilución o en el mercado.

Omeros Corporation (OMER)는 Form 4를 제출하여 비임원 이사인 Dr. Leroy E. Hood가 2025년 6월 27일에 연간 주식매수선택권 15,000주를 부여받았음을 공개했습니다. 이 옵션은 행사가격이 3.20달러이며, 10년 만기로 2035년 6월 27일에 만료되고, 2026년 연례 주주총회 전날에 전액 취득 조건이며, 그가 이사로 남아 있는 경우에 한합니다. 보통주에 대한 공개 시장에서의 매매는 보고되지 않았으며, 표 I에서는 비파생 주식 소유에 변화가 없습니다. 이 제출은 정기적인 이사 보상을 반영하며 Omeros의 총 발행 주식 중 극히 일부에 해당하여 즉각적인 희석이나 시장 영향이 거의 없음을 의미합니다.

Omeros Corporation (OMER) a déposé un formulaire 4 indiquant que le directeur non salarié Dr Leroy E. Hood a reçu une attribution annuelle d’options sur actions pour 15 000 actions le 27 juin 2025. L’option comporte un prix d’exercice de 3,20 $, une durée de 10 ans expirant le 27 juin 2035, et sera entièrement acquise la veille de l’assemblée annuelle des actionnaires de 2026, à condition qu’il reste directeur. Aucun achat ou vente d’actions ordinaires sur le marché ouvert n’a été signalé, et le tableau I ne montre aucun changement dans la détention d’actions non dérivées. Le dépôt reflète la rémunération habituelle des administrateurs et représente une part négligeable du total des actions en circulation d’Omeros, impliquant un impact immédiat minimal en termes de dilution ou sur le marché.

Omeros Corporation (OMER) hat ein Formular 4 eingereicht, in dem offengelegt wird, dass der nicht-geschäftsführende Direktor Dr. Leroy E. Hood am 27. Juni 2025 eine jährliche Aktienoptionszuteilung für 15.000 Aktien erhalten hat. Die Option hat einen Ausübungspreis von 3,20 $, eine Laufzeit von 10 Jahren bis zum 27. Juni 2035 und wird am Tag vor der jährlichen Hauptversammlung 2026 vollständig unverfallbar, vorausgesetzt, er bleibt Direktor. Es wurden keine Käufe oder Verkäufe von Stammaktien am offenen Markt gemeldet, und Tabelle I zeigt keine Änderung im Besitz nicht-derivativer Aktien. Die Meldung spiegelt die routinemäßige Vergütung von Direktoren wider und stellt einen vernachlässigbaren Anteil der insgesamt ausstehenden Aktien von Omeros dar, was auf eine minimale unmittelbare Verwässerung oder Marktwirkung hindeutet.

0001501570false00015015702025-06-302025-06-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
 

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
 
Date of Report (date of earliest event reported): June 30, 2025


VERITEX HOLDINGS, INC.
(Exact name of Registrant as specified in its charter) 
 
Texas 001-36682 27-0973566
(State or other jurisdiction of
incorporation or organization)
 (Commission File Number) (I.R.S. Employer
Identification Number)
 
8214 Westchester Drive, Suite 800
Dallas, Texas 75225
(Address of principal executive offices)
 
(972) 349-6200
(Registrant’s telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)
  
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
Common Stock, par value $0.01 per shareVBTXNasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o




Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Retirement of Mr. Terry Earley as Chief Financial Officer

As previously disclosed by Veritex Holdings, Inc. (the “Company”) in its Current Report on Form 8-K filed with the Securities and Exchange Commission (“SEC”) on January 29, 2025, Senior Executive Vice President and Chief Financial Officer, Terry S. Earley retired effective June 30, 2025. In connection with Mr. Earley’s retirement as Chief Financial Officer, Mr. Earley and the Company entered into a Consulting Agreement (the “Consulting Agreement”) whereby Mr. Earley will serve as a consultant to the Company beginning on July 1, 2025.

During the term of the Consulting Agreement, Mr. Earley will provide consulting services to the Company, and the Company will pay Mr. Earley up to $165,000 per year in equal monthly installments, which includes a monthly expense stipend. The Consulting Agreement has an initial term of one year and may be extended an additional year as provided in the Consulting Agreement. The Consulting Agreement may be terminated by either party at any time without cause upon 90 days’ notice or by the Company for cause upon 3 days’ notice, and also contains customary covenants, terms and conditions, including provisions concerning confidentiality.

Effective as of July 1, 2025, Mr. Earley became a member of the Board of Directors of Veritex Community Bank, which such role shall entitle Mr. Earley to compensation in his capacity as a member of such Board of Directors.

Appointment of Mr. William Holford as Chief Financial Officer

As previously disclosed by Veritex in its Current Report on Form 8-K filed with the SEC on January 29, 2025, William L. Holford was appointed as the Company’s Executive Vice President and Chief Financial Officer effective July 1, 2025. Mr. Holford, age 42, most recently served as the Veritex Community Bank (the “Bank”) Executive Vice Present, Director of Strategic Corporate Development. Mr. Holford has 20 years in the financial services industry and joined Veritex in 2011. While at Veritex, Mr. Holford has held various positions including Controller, Treasurer and Director of Strategic Corporate Development. Mr. Holford has and will continue to work closely with Mr. Earley to ensure a smooth transition.

In connection with Mr. Holford’s appointment, Mr. Holford and the Company entered into an Executive Employment Agreement, dated July 1, 2025. Pursuant to the Executive Employment Agreement, Mr. Holford will receive an annual base salary of $450,000 and will be eligible to participate in the Company’s annual and long-term incentive compensation plan for the Company’s senior executives at a level to commensurate with his position.

Pursuant to the Executive Employment Agreement, if Mr. Holford’s employment is terminated by the Company without cause or by him for good reason (such a termination, an “involuntary termination”), prior to or more than 24 months after a change of control, Mr. Holford will be entitled to receive the following severance payments and benefits, subject to execution and non-revocation of a release of claims: (i) an amount equal to 12 months of Mr. Holford’s base salary plus a cash payment equal to one times the average annual cash incentive bonus paid to Mr. Holford for the two full calendar years immediately preceding the date of his involuntary termination; (ii) an annual cash incentive bonus payment for the year in which the involuntary termination occurs, subject to achievement of the applicable performance criteria relating to payment of such bonus, pro-rated based on the number of days Mr. Holford was employed during the performance year; and (iii) a cash payment equal to 12 months of the Consolidated Omnibus Budget Reconciliation Act (“COBRA”) premium in effect at the time of Mr. Holford’s involuntary termination.

Upon an involuntary termination that occurs on or within 24 months of a change of control, Mr. Holford will be entitled to receive the following severance payments and benefits, subject to execution and non-revocation of a release of claims: (i) an amount equal to 30 months of Mr. Holford’s base salary plus a cash payment equal to two and a half times the average annual cash incentive bonus paid to Mr. Holford for the two full calendar years immediately preceding the date of his involuntary termination; (ii) an annual cash incentive bonus payment for the year in which the involuntary termination occurs, subject to achievement of the applicable performance criteria relating to payment of such bonus, pro-rated based on the number of days Mr. Holford was employed during the performance year; and (iii) a cash payment equal to 18 months of the COBRA premium in effect at the time of Mr. Holford’s involuntary termination.

Mr. Holford’s Executive Employment Agreement also contains non-competition, non-solicitation and non-recruitment covenants, as well as customary confidentiality, non-disparagement and cooperation covenants.

There are no arrangements between Mr. Holford and the Company regarding his appointment as CFO. There are no family relationships between Mr. Holford and any of the Company’s executive officers and directors. Mr. Holford is not a party to any



transaction with the Company that might require disclosure under Item 404(a) of Regulation S-K under the Securities Act of 1933, as amended (the “Securities Act”).


Cautionary Note Regarding Forward-Looking Statements

This report contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Generally, words such as “anticipate,” “estimate,” "will", “expect,” “project,” “intend,” “believe,” “plan,” “target,” “forecast” and similar expressions are intended to identify forward-looking statements. Such forward-looking statements concern management’s expectations, strategic objectives, business prospects, anticipated economic performance and financial condition and other similar matters. Forward-looking statements are inherently uncertain and subject to a variety of assumptions, risks and uncertainties that could cause actual results to differ materially from those anticipated or expected by the management of Veritex. These statements are not guarantees of future performance and actual events or results may differ significantly from these statements. Actual events or results are subject to significant known and unknown risks, uncertainties and other important factors, many of which are beyond Veritex’s control and are described in Veritex’s filings with the United States Securities and Exchange Commission (the “SEC”). It should be understood that it is not possible to predict or identify all such factors. Given these risk factors, investors and analysts should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date of the document in which they are made. Veritex disclaims any obligation or undertaking to provide any updates or revisions to any forward-looking statement to reflect any change in Veritex’s expectations or any change in events, conditions or circumstances on which the forward-looking statement is based, except as required by law. It is advisable, however, to consult any further disclosures Veritex makes on related subjects in its filings with the SEC, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, if any. These statements constitute Veritex’s cautionary statements under the Private Securities Litigation Reform Act of 1995.






SIGNATURES
 
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Veritex Holdings, Inc.
  
By:/s/ C. Malcolm Holland, III
 C. Malcolm Holland, III
 Chairman and Chief Executive Officer
Date:7/1/2025
 


FAQ

What insider activity did OMER report on the July 1, 2025 Form 4?

Director Dr. Leroy E. Hood received an option to purchase 15,000 shares at $3.20 per share.

When will the 15,000 OMER options vest and expire?

They fully vest the day before the 2026 annual meeting and expire on 27 Jun 2035.

Were any OMER common shares bought or sold in the filing?

No. The Form 4 lists only the option grant; no open-market share transactions occurred.

Does the option grant materially dilute existing shareholders?

The 15,000-share grant is immaterial relative to Omeros’ total share count; dilution impact is negligible.

Is this option award part of a pre-established compensation policy?

Yes. Omeros automatically grants each long-serving non-employee director 15,000 options at every annual meeting.
Veritex Holdings

NASDAQ:VBTX

VBTX Rankings

VBTX Latest News

VBTX Latest SEC Filings

VBTX Stock Data

1.42B
52.11M
3.78%
93.36%
2.48%
Banks - Regional
State Commercial Banks
Link
United States
DALLAS